Literature DB >> 3942624

Relative frequency of inferior vestibular schwannoma.

J D Clemis, W J Ballad, P J Baggot, S T Lyon.   

Abstract

Until quite recently, acoustic tumors were not diagnosed until they had reached relatively large size. Vestibular function tests were positive in a large percentage of these cases. Since vestibular function tests are limited to lesions of the superior branch of the vestibular nerve, it was thought that 90% of vestibular schwannomas arose from the superior vestibular nerve. Recently, as the diagnostic efficiency of auditory tests has improved, many small tumors are being detected. As the size of the tumors decreases, the efficiency of vestibular function testing has also decreased. A review of histologic and surgical literature demonstrates that the earlier estimate is inaccurate, and that only 50% of vestibular schwannomas originate on the superior branch of the vestibular nerve. This warrants a critical review of the value of vestibular function tests in the evaluation of suspected vestibular schwannomas.

Entities:  

Mesh:

Year:  1986        PMID: 3942624     DOI: 10.1001/archotol.1986.03780020070016

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  9 in total

1.  Chances of Improvement in Cases of Vestibular Schwannoma Presenting with Facial Nerve Weakness: Presentation of Two Cases and Literature Review.

Authors:  Ahmed R Rizk; Marcus Mehlitz; Martin Bettag
Journal:  J Neurol Surg B Skull Base       Date:  2018-07-03

2.  Role of magnetic resonance imaging in evaluation of cerebellopontine angle schwannomas.

Authors:  Kunwarpal Singh; Mohit Preet Singh; Cl Thukral; Kiran Rao; Kulvinder Singh; Amandeep Singh
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-06-24

3.  3D quantitative assessment of response to fractionated stereotactic radiotherapy and single-session stereotactic radiosurgery of vestibular schwannoma.

Authors:  T Schneider; J Chapiro; M Lin; J F Geschwind; L Kleinberg; D Rigamonti; I Jusué-Torres; A E Marciscano; D M Yousem
Journal:  Eur Radiol       Date:  2015-07-03       Impact factor: 5.315

4.  Dumbbell schwannomas of the internal auditory canal.

Authors:  K L Salzman; H C Davidson; H R Harnsberger; C M Glastonbury; R H Wiggins; S Ellul; C Shelton
Journal:  AJNR Am J Neuroradiol       Date:  2001-08       Impact factor: 3.825

5.  Preoperative vestibular evoked myogenic potentials (VEMPs), caloric test, and pure tone audiometry to identify the vestibular nerve branch of schwannoma origin: preliminary results in a series of 26 cases.

Authors:  Francesca Cianfrone; Italo Cantore; Raffaelino Roperto; Francesco Tauro; Francesco Bianco; Luciano Mastronardi; Paolo Ruscito
Journal:  Neurosurg Rev       Date:  2022-07-12       Impact factor: 2.800

6.  Double localization of a unilateral sporadic vestibular schwannoma.

Authors:  M Barbara; F Ronchetti; V Manni; S Monini
Journal:  Acta Otorhinolaryngol Ital       Date:  2008-02       Impact factor: 2.124

7.  Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2.

Authors:  Stavros M Stivaros; Anat O Stemmer-Rachamimov; Robert Alston; Scott R Plotkin; Joseph B Nadol; Alicia Quesnel; Jennifer O'Malley; Gillian A Whitfield; Martin G McCabe; Simon R Freeman; Simon K Lloyd; Neville B Wright; John-Paul Kilday; Ian D Kamaly-Asl; Samantha J Mills; Scott A Rutherford; Andrew T King; D Gareth Evans
Journal:  J Med Genet       Date:  2015-06-23       Impact factor: 6.318

8.  Significance of Vestibular Testing on Distinguishing the Nerve of Origin for Vestibular Schwannoma and Predicting the Preservation of Hearing.

Authors:  Yu-Bo He; Chun-Jiang Yu; Hong-Ming Ji; Yan-Ming Qu; Ning Chen
Journal:  Chin Med J (Engl)       Date:  2016-04-05       Impact factor: 2.628

9.  Ocular torsion responses to electrical vestibular stimulation in vestibular schwannoma.

Authors:  Stuart W Mackenzie; Richard Irving; Peter Monksfield; Raghu Kumar; Attila Dezso; Raymond F Reynolds
Journal:  Clin Neurophysiol       Date:  2018-09-08       Impact factor: 3.708

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.